Imagine the medicine used to treat cancer as a tiny, guided missile that needs a specific kind of nuclear fuel to work. Right now, Europe struggles to get enough of this fuel, and some of the best types are hard to make. This work finds better ways to produce these fuels and ensures they can be delivered safely to hospitals.
The demand for cancer-treating radionuclides is growing faster than the ability to produce them. This creates a supply gap and technical barriers in target preparation and safe handling.
Innovative production routes for 7 specific isotopes and new irradiation target designs including recycling procedures.
If you are a drug manufacturer dealing with the shortage of alpha-emitters like Ac-225 — this project developed innovative production routes and target preparation methods that increase the availability of these critical materials.
If you are a clinic dealing with safety risks when handling new isotopes — this project developed radiation risk assessments and safe handling recommendations for workers and patients.
If you are a production facility dealing with inefficient target materials — this project developed new irradiation target designs and recycling procedures to make production more sustainable.
Based on available project data, specific cost or pricing information for the production methods is not provided.
The project specifically aimed to provide lessons learned as a demonstration case for upscaling and sustained isotope production.
Based on available project data, there is no explicit mention of patents or licensing agreements, though results were supported by scientific publications.
The project developed a guidance and recommendations framework to enable the safe application and clinical potential of alpha and beta particle therapy.
The project period runs from 2022-10-01 to 2025-09-30, indicating the window for these developments.
The consortium is heavily weighted toward research and academic expertise, with 10 research organizations and 3 universities. However, it maintains a practical edge with 3 industrial partners and 2 SMEs, representing a 17% industry ratio. This structure suggests the project is primarily focused on technical breakthroughs and validation rather than immediate commercial rollout.
Contact Narodowe Centrum Badan Jadrowych in Poland
Contact us to find the specific production route for your target isotope.
